Grace Therapeutics (GRCE) Non Operating Income (2019 - 2026)
Grace Therapeutics (GRCE) posted Non Operating Income of $132000.0 for Q1 2026, down 1.49% sequentially from $134000.0 in Q4 2025, and down 95.29% YoY from $2.8 million in Q1 2025.
Grace Therapeutics (GRCE) Non Operating Income (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $132000.0 in Q1 2026.
- Quarterly Non Operating Income fell 95.29% year-over-year to $132000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 59.5% YoY) and the FY2026 annual result came in at $1.6 million, down 59.51% from the prior year.
- Non Operating Income slipped to $132000.0 in Q1 2026 per GRCE's latest filing, from $134000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $2.8 million in Q1 2025 and troughed at -$1.6 million in Q3 2023.
- A 5-year average of $217764.7 and a median of $115000.0 in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income plunged 6879.17% in 2023, then jumped 1042.25% in 2024.
- Over 5 years, Non Operating Income stood at $82000.0 in 2022, then jumped by 441.46% to $444000.0 in 2023, then tumbled by 337.84% to -$1.1 million in 2024, then surged by 112.69% to $134000.0 in 2025, then dropped by 1.49% to $132000.0 in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $132000.0, $134000.0, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 127,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 127,000.00 |
| Mar 31, 2026 | 132,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | -272,000.00 |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | -1.06 Mn |
| Sep 30, 2024 | 547,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | -792,000.00 |
| Dec 31, 2023 | 444,000.00 |
| Sep 30, 2023 | -1.63 Mn |
| Jun 30, 2023 | 142,000.00 |
| Mar 31, 2023 | 115,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | -36,000.00 |
| Mar 31, 2022 | -149,000.00 |
| Dec 31, 2021 | 696,000.00 |
| Sep 30, 2021 | 4.55 Mn |